Introduction
Perioperative acute kidney injury (AKI) is a common problem with an associated increase in risk for shortterm mortality, long-term mortality and chronic kidney disease [1, 2] . Typically occurring in 20-30% of patients undergoing cardiac surgery [3] , recent data suggests that it may also occur in more than 30% of patients undergoing major non-cardiac surgeries [4] . Clinical trials seek to evaluate the impact of interventions on a variety of primary and secondary endpoints with the aim of implementing this knowledge to improve perioperative outcomes. However, the use of valid and relevant endpoints within such trials is pivotal to achieving this goal [5, 6] .
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Abstract
Perioperative acute kidney injury is a common problem. While clinical trials seek to evaluate the impact of interventions on a variety of primary and secondary endpoints with the aim of implementing this knowledge to improve perioperative outcomes, the use of valid and relevant endpoints within clinical trials is of critical importance to achieving this goal. Suitable endpoints must be validated for the study population and in light of the clinical context under investigation while also considering regulatory requirements that govern the licensing of new therapeutic agents as well as the values of patients whose outcomes we seek to improve. Heterogeneity in perioperative clinical trial endpoints and their definitions limits the ability to compare and interpret differences in outcomes across studies or to pool outcomes from different studies in meta-analysis. The Standardized Endpoints in Perioperative Medicine (StEP) initiative is an international collaboration whose goal is to identify and recommend a suite of clearly and precisely defined endpoints across multiple domains, specifically suited for use in perioperative clinical trials. The current review describes the rationale, goals and the planned pathway of the StEP renal subgroup. Development of a set of standardized and core renal endpoints, valid and relevant for use in the perioperative Selected endpoints must be validated for the study population and clinical context under investigation [5] while also considering regulatory requirements for licensing novel therapeutic interventions as well as the values of patients whose outcomes we seek to improve [7, 8] . Moreover, the consistent use of standardized and precisely defined endpoints is essential to facilitate the meaningful comparison of outcomes between studies as well as the pooling of results for subsequent meta-analysis [5] .
This review describes a current, international collaboration whose goal is to identify and recommend a suite of clearly and precisely defined renal endpoints specifically suited for use in perioperative clinical trials [5] . The intent is to optimize the validity, reproducibility, comparability and utility of renal outcomes measured and reported in clinical trials from this evolving discipline.
The Need for a Standardized and Core Set of Perioperative Renal Outcomes
The critical importance of developing specialty-specific core outcomes sets, consistently reported by all clinical trials within a given specialty, is increasingly recognized [9] and embodied by the current Core Outcome Measures in Effectiveness Trials initiative (www.comet-initiative. org). The Core Outcome Measures in Perioperative and Anaesthetic Care group exists under this umbrella, seeking to develop a core outcome set for anesthesia and perioperative medicine. A European Society of Anesthetists/ European Society of Intensive Care Medicine joint taskforce recently made initial recommendations to identify and define a broad, multi-system raft of perioperative outcomes [6] . While recommending unmodified use of the kidney disease improving global outcomes (KDIGO) criteria for perioperative AKI, they acknowledged that these initial recommendations need to be broadened and refined, reflecting that the full significance of perioperative complications may require significantly longer than 30 or even 90 days after surgery to become fully known [10] .
Enormous variability in renal endpoints and their definitions within existing clinical research studies helped provide the impetus for consensus statements that defined the concept of AKI more than a decade ago and unquestionably advanced the field. First published in 2004 as the RIFLE criteria, diagnostic criteria for AKI have now evolved into the KDIGO criteria, defining and staging AKI by either absolute or proportionate changes in serum creatinine or increasing degrees of oliguria. While the need for uniform diagnostic criteria for AKI within clinical trials is widely agreed upon, the extent to which such uniformity has been achieved in perioperative trials remains unknown. Moreover, the question of whether current KDIGO consensus criteria for AKI provide the most appropriate renal endpoint for the perioperative setting, either alone or combined with other metrics, warrants careful consideration.
What Perioperative Renal Outcomes should be Measured?
Short-term creatinine-based outcomes are consistently associated with adverse perioperative outcomes but remain a biochemical surrogate with significant limitation [11] . Characteristic features of the perioperative period, including large volume fluid administration, poorly defined changes in creatinine production rate and an intense neuro-humoral stress response, may further limit the suitability of short-term creatinine-based or oliguria-based endpoints in this context. While calls for "hard" or longer-term outcomes are well reasoned, varied indications for the use of renal replacement therapy in clinical practice together with a low incidence of perioperative use, potential competing risk issues associated with early mortality and typically limited follow-up beyond hospital discharge highlight the challenge of selecting and defining optimal renal endpoints for perioperative trials.
The US Food and Drug Administration does not consider preventing an increase in serum creatinine sufficient evidence to register a putative nephroprotective agent [12] ; instead it requires evidence that an agent reduces adverse clinical outcomes. A recent systematic review failing to find difference in rates of CKD or mortality ≥90 days after surgery in clinical trials where the intervention demonstrated a significant impact on short-term serum creatinine levels [13] , including the AKI sub-study of the CORONARY trial [14] , supports such a stance. Although seldom reported in existing trials, observational data suggests the importance of perioperative renal outcomes beyond the incidence of AKI identified within 7 days after surgery [12, 15, 16] Standardized, validated and patient-centered outcome measures are the fundamental building blocks on which high-quality comparative effective trials must be based in order for evidence-based medicine to deliver enhanced outcomes for all stakeholders [5] . Developing a core set of standardized outcomes within any given perioperative domain would enhance the value of subsequent systematic reviews seeking to pool outcomes from multiple studies and thus provide greater precision of effect estimates or aid in the planning of large and definitive perioperative trials.
In 2015, a group of experienced perioperative clinical trialists met to establish a consensus process for standardizing endpoints in perioperative medicine [5] . This Standardized Endpoints in Perioperative Medicine (StEP) group is currently developing expert and consensus-based guidelines for a broad suite of precisely defined and standardized endpoints across multiple perioperative domains that will feed into the parallel development of core outcome sets for peri operative studies by the Core Outcome Measures in Perioperative and Anaesthetic Care initiative (online supplement Fig. 1, see www. karger.com/ doi/10.1159/000478055).
StEP Renal Endpoints
Under the guidance of the StEP steering committee, groups of 4-8 geographically diverse experts in perioperative medicine were assembled to address the issue of endpoints for specific perioperative domains. The renal endpoints group consists of 6 individuals, each with perioperative trials experience and background training in anesthesiology, critical care medicine or nephrology. The objective was to (1) identify renal endpoints currently used in perioperative clinical trials through a process of systematic review, (2) through appropriate summary of this literature and expert opinion, initiate a modified Delphi consensus process to propose metrics of renal injury and function best suited for use in perioperative medicine trials, and (3) incorporate the results of this process into the international StEP initiative.
After developing and agreeing on a protocol, an initial systematic review addressed the question: which endpoints are currently used to measure perioperative renal injury and function in clinical trials published in the anaesthetic, surgical, medical, critical care, cardiovascular and nephrology literature? Randomised controlled trials of perioperative interventions including ≥100 patients for analysis, reporting renal outcomes and published after January 1, 2004 in a priori identified high-impact journals, were identified through Medline to facilitate a qualitative analysis of contemporary perioperative renal outcomes.
Preliminary review suggested large variation in reported outcomes across studies with definitions that were frequently short term as well as imprecise or ambiguous, with the overwhelming majority reporting the effect of interventions on prevention rather than treatment of renal injury. None of the included studies used the major adverse kidney endpoint (MAKE) composite recently described [17] , and few reported any metrics of renal recovery. In parallel with this process, an initial long list of proposed renal endpoints for the perioperative community, comprising 10 endpoints (8 single and 2 composite) reflecting expert opinion and literature beyond published perioperative trials has been drafted without specific designation of endpoint suitability for trials of preventive vs. treatment interventions. A structured, modified Delphi process will ask parti cipants to score each endpoint according to perceived importance. Participants will have the opportunity to add other endpoints or suggest modification to endpoints presented on this initial list. Through this process, a reduced number of precisely defined and standardized renal endpoints for perioperative clinical trials will be identified. Based on available data and expert opinion, each endpoint will then be rated on validity, reliability, feasibility and patient-centeredness.
Resource constraints together with varied aims and priorities associated with evolving phases of clinical trials mean that the most appropriate renal endpoint(s) may vary between study type and setting. To enhance the utility of proposed recommendations, it is further anticipated that a statement regarding context sensitivity will accompany each recommended endpoint. Nevertheless, the identification of one or more core endpoints, supported by expert opinion and recommended for reporting (where feasible) regardless of study phase or sample size, will enhance the value of subsequent pooled analyses for any given intervention. Results will be reported according to current recommendations [18, 19] , with periodic updates anticipated as new evidence emerges.
